Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Notebook: Valneva Vaccine To Begin EU Rolling Review, Synairgen Reports Progress With Inhaled IFN-Beta

Executive Summary

The European Parliament is pushing for more of a say in how Europe’s new emergency response authority, HERA, deals with R&D and procurement of vaccines and therapies in times of health crises. NRx Therapeutics says it will continue to seek US approval of aviptadil for COVID-19. 

You may also be interested in...



EU Launches New Response Body To Tackle Future Health Emergencies

The European Commission has dismissed concerns about the operation of its new emergency response body, saying it will ensure the EU is well prepared for tackling future pandemics and other threats. HERA will complement, not duplicate, work conducted by existing agencies such as the European Medicines Agency, delegates heard at this week’s European Health Forum Gastein virtual conference.

EU Legislators Firm Up Commission’s Plans To Overhaul Pharma Rules

Efforts to overhaul the EU pharmaceutical legislation have been given added impetus after the European Parliament called for action to boost innovation and medicines access, shore up manufacturing and supply chains, and examine the link between R&D spending and drug prices.

Comirnaty mRNA Vaccine First To Get EU Clearance For Under-12s

The EMA is going all out to maximize coverage of the EU population with both vaccines and treatments for COVID-19.

Topics

Related Companies

UsernamePublicRestriction

Register

PS145237

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel